Looking for personalised treatments in chordoma: benefit of olaparib in a BRCA2-mutated patient
Hospital Garcia de Orta, Almada, Portugal
Instituto Portuguęs de Oncologia Porto Francisco Gentil, Porto, Portugal
Contemp Oncol (Pozn) 2026; 30 (3)
Data publikacji online: 2026/10/19
- Yu E, Koffer PP, DiPetrillo TA, Kinsella TJ. Incidence, treatment, and survival patterns for sacral chordoma in the United States, 1974–2011. Front Oncol 2016; 6: 203.
- Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Fer- reira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol 2012; 13: e69-76.
- Stacchiotti S, Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015; 16: e71-83.
- Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Bone sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 1520-1536.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2024.
- Dial BL, Kerr DL, Lazarides AL, Catanzano AA, Green CL, Risoli T Jr, et al. The role of radiotherapy for chordoma patients managed with surgery: analysis of the National Cancer Database. Spine (Phila Pa 1976) 2020; 45: E742-E751.
- Sharifnia T, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, et al. Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med 2019; 25: 292-300.
- Raygada M, John L, Liu A, Schultz J, Thomas BJ, Bernstein D, et al. Germline findings in cancer predisposing genes from a small cohort of chordoma patients. J Cancer Res Clin Oncol 2024; 150: 227.
- Xia B, Biswas K, Foo TK, Torres T, Riedel-Topper M, Southon E, et al. Rare germline variants in PALB2 and BRCA2 in familial and sporadic chordoma. Hum Mutat 2022; 43: 1396-1407.
- Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröh-lich M, et al. Defective homologous recombination DNA repair as a therapeutic target in advanced chordoma. Nat Commun 2019; 10: 1635.
- Yepes S, Shah NN, Bai J, Koka H, Li C, Gui S, et al. Rare germline variants in chordoma-related genes and chordoma susceptibility. Cancers (Basel) 2021; 13: 2704.
- Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017; 355): 1152-1158.
- Hsia B, Bitar G, Alshaka SA, Kim JD, Valencia-Sanchez BA, Faraji F, et al. Genomic characterization of chordoma: insights from the AACR Project GENIE database. Cancers (Basel) 2025; 17: 536.
- Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19: 77-87.
- Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and other cancers for BRCA1 and BRCA2 mutation carriers. JAMA. 2017; 317: 2402-2416.
- Mateo J, Lord CJ, Serra V, Tutt A, Balmańa J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019; 30: 1437-1447.
- Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst 2018; 110: 714-725. doi:10.1093/jnci/djx265.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
